Mark Blumenkranz

Mark Blumenkranz is Kedalion’s Chairman, Chief Executive Officer, and Co-Founder, and also the Chairman and Managing Director of Lagunita Biosciences, a venture incubator that creates and grows early-stage companies to commercialize impactful translational science that addresses significant clinical needs. Dr. Blumenkranz is now the HJ Smead Professor Emeritus at the Byers Eye Institute and Department of Ophthalmology at Stanford University and served as departmental Chairman from 1997 to 2015. He played a leading role in the planning, fundraising, and construction of the Institute which opened in 2010. Mark has a longstanding interest and expertise in university corporate technology transfer and early-stage biomedical companies and was a Founder and Director of Macusight, Peak Surgical, Optimedica Corporation, Adverum Biotechnologies, Oculeve, and Digisight Corporation (now Verana Heath). He has also served on the Boards of Directors of a number of other private and publicly traded ophthalmic drug and medical device companies including Oculex Pharmaceuticals, OIS, Midlabs, Presbia, and Beaver-Visitec (BVI Inc). He completed the Stanford Executive Program in the Graduate School of Business in 2004 and received his Undergraduate, Master's degree in biochemical pharmacology, and MD degrees from Brown University (AOA), where he is also a Fellow of the Corporation and immediate past Chair of the Medical School Committee.